



Published in final edited form as:

*J Adolesc Health*. 2013 December ; 53(6): . doi:10.1016/j.jadohealth.2013.07.006.

## NEUROCOGNITIVE FUNCTIONING IN ANTIRETROVIRAL THERAPY-NAÏVE YOUTH WITH BEHAVIORALLY ACQUIRED HIV

Sharon L. Nichols, PhD<sup>1</sup>, James Bethel, PhD<sup>2</sup>, Patricia A. Garvie, PhD<sup>3</sup>, Doyle E Patton, PhD<sup>4</sup>, Sarah Thornton, BS<sup>2</sup>, Bill G. Kapogiannis, MD<sup>5</sup>, Weijia Ren, PhD<sup>2</sup>, Hanna Major-Wilson, MSN<sup>6</sup>, Ana Puga, MD<sup>4</sup>, Steven P. Woods, PsyD<sup>7</sup>, and the Adolescent Trials Network for HIV/AIDS Interventions

<sup>1</sup>Department of Neurosciences, University of California, San Diego, La Jolla, California <sup>2</sup>Westat, Rockville, Maryland <sup>3</sup>Consultant, Memphis, Tennessee\* <sup>4</sup>Children's Diagnostic & Treatment Center, Inc., Ft. Lauderdale, Florida <sup>5</sup>National Institutes of Health, Bethesda, MD <sup>6</sup>Department of Pediatrics, Division of Adolescent Medicine, University of Miami, Miami, Florida <sup>7</sup>Department of Psychiatry, University of California, San Diego, La Jolla, California

### Abstract

**Purpose**—Youth living with HIV account for over one-third of new HIV infections and are at high risk of adverse psychosocial, everyday living, and health outcomes. HIV-associated neurocognitive disorders (HAND) are known to affect health outcomes of HIV-infected adults even in the era of combination antiretroviral therapy (cART). Thus, the current study aimed to characterize the prevalence and clinical correlates of HAND in youth living with HIV. Here we report baseline neurocognitive data for behaviorally HIV-infected youth enrolled in a prospective study evaluating strategies of antiretroviral treatment initiation and use.

**Methods**—Two hundred twenty participants, age 18-24, naïve to treatment (except for prevention of mother to child HIV transmission; n=3), completed a comprehensive neurocognitive, substance use, and behavioral health assessment battery.

**Results**—64.7% of youth met criteria for HAND (96.4% asymptomatic, 3.5% syndromic), with deficits in episodic memory and fine-motor skills emerging as the most commonly affected ability areas. Multivariable models showed that lower CD4 count, longer time since HIV diagnosis, and high risk alcohol use were uniquely associated with neurocognitive deficits.

---

© 2013 Society for Adolescent Medicine. Published by Elsevier Inc. All rights reserved.

Corresponding author: Sharon L. Nichols Department of Neurosciences University of California, San Diego 9500 Gilman Drive, #0935 La Jolla, California 92093 Telephone: (858) 822-6700 Fax: (858) 822-6707 slnichols@ucsd.edu.

\*Dr. Garvie's role on the project was initiated while on faculty at St. Jude Children's Research Hospital. At the time of manuscript submission, Dr. Garvie's continued participation is as a contracted consultant.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Implications and Contribution** Youth with behaviorally acquired HIV demonstrate high rates of cognitive impairment. Impairment in certain domains is related to HIV disease severity and to alcohol use. This impairment could have implications for functional and behavioral outcomes and raises concerns about subtle central nervous system changes early in infection.

No authors declared conflicts of interest related to the work reported herein.

The first draft of the manuscript was written by Nichols, Bethel, Garvie, Patton, Kapogiannis, Ren, and Woods. No payment was provided for writing of this paper.

**Conclusions**—Over two-thirds of youth with behaviorally acquired HIV evidence neurocognitive deficits, which have modest associations with more advanced HIV disease as well as other factors. Research is needed to determine the impact of such neuropsychiatric morbidity on mental health and HIV disease treatment outcomes (e.g., non-adherence) and transition to independent living responsibilities in HIV-infected youth, as well as its long-term trajectory and possible responsiveness to cognitive rehabilitation and pharmacotherapy.

### Keywords

HIV; Adolescent; Neurocognitive Functioning; Substance Use; HIV-Associated Neurocognitive Disorder (HAND)

---

### Introduction

Adolescents and young adults experience the highest risk for HIV infection of any age group, accounting for 39% of new infections<sup>1</sup>. This population also presents unique clinical and public health challenges due to higher rates of poor medication adherence<sup>2</sup> and sexual and substance risk behaviors<sup>3</sup>. Interventions and changes in treatment recommendations for behaviorally infected youth living with HIV (YLWH), such as initiation of combination antiretroviral therapy (cART) at the time of diagnosis, have been implemented in the absence of knowledge regarding their neurocognitive functioning. Cognitive and functional impairments, whether HIV-related or due to other risk factors, may have implications for intervention development and long-term disease and treatment monitoring specifically tailored for adolescents.

The potential public relevance of neurocognitive impairment among YLWH is supported by over two decades of clinical research in adults<sup>4</sup> and children with perinatally acquired HIV (pHIV) or HIV acquired through blood products used to treat hemophilia<sup>5,6</sup>. Approximately 30-50% of HIV-infected adults demonstrate HIV-Associated Neurocognitive Disorders (HAND); in fact, the prevalence of mild-to-moderate neurocognitive deficits has increased in the cART era among persons with less advanced HIV disease<sup>7</sup>. Consistent with its preferential effects on the frontostriato-thalamo-cortical systems, HIV infection is marked by deficits in executive functions (e.g., planning), memory, and psychomotor speed, with relative sparing of basic language and visuoconstruction skills<sup>4</sup>. HAND has been linked to a variety of clinical factors, including alcohol and substance abuse<sup>8,9</sup>, lower nadir CD4 counts<sup>10</sup>, and lower cognitive reserve<sup>11</sup>. HIV-associated neurocognitive impairment increases risk of dependence in activities of daily living (ADL), including cART non-adherence<sup>12</sup>. Children and youth with pHIV show a different neurocognitive profile, with impairments in language and global functioning in addition to those seen in adults<sup>6</sup>. Those with HIV acquired postnatally through hemophilia treatment showed declines over time in nonverbal skills, memory, language, and academics that correlated with immunological changes<sup>5</sup>.

We are unaware of any large-scale neurocognitive studies of adolescents and emerging adults with behaviorally acquired HIV to date. One study of behaviorally infected YLWH that included measures of cognition<sup>13</sup> found impairments in word knowledge and delayed development of abstract reasoning. The potential implications of cognitive impairments in YLWH differ from those in adults, emphasizing the need for studies targeted towards this age group. Adolescence and young adulthood are developmental periods characterized by acquisition of skills essential for successful transition to independent adulthood occurring simultaneously with increased experimentation and risk taking. Both of these occur in the context of ongoing brain development, including frontostriatal systems vulnerable to HIV<sup>14</sup>. Furthermore, youth may differ from adults in their profile of substance use, psychiatric and

other comorbidities. Here we report cross-sectional data regarding neurocognitive functioning in treatment naive youth with behaviorally acquired HIV and exploratory analyses of its relationship to HIV disease severity, demographics, substance use, and psychiatric comorbidity.

## Methods

### Participants

Youth aged 18-24 years with behaviorally acquired HIV infection were enrolled from among clinical patients followed at 15 Adolescent Medicine Trials Network for HIV/AIDS Interventions and 12 International Maternal Pediatric Adolescent AIDS Clinical Trials sites across the US and Puerto Rico into a prospective cohort study evaluating neurocognitive functioning in participants with different illness severity and indications for treatment. At the time this study was initiated, the US Department of Health and Human Services Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents (Guidelines) recommended starting cART in patients whose CD4+ T-cells were <350 or HIV RNA >100,000 copies/mL plasma, in absence of clinical or psychosocial contraindications. Participants enrolled into four groups, two groups not yet meeting Guidelines, half of whom were randomized to initiate early ART within a treatment strategy study, and two groups who met Guidelines and either started treatment or did not due to patient preference or provider concerns about adherence. For the present analysis of baseline neurocognitive functioning, all groups were combined and CD4+ count was treated as a continuous variable. All participants were treatment naive except for <6 months ART to prevent mother-to-child HIV transmission (PMTCT; n=3). Self-reported English or Spanish fluency was required. Exclusion criteria included prior ART experience other than PMTCT, current pregnancy, active substance use or dependence judged likely to interfere with study requirements, psychosis, or significant non-HIV-related cognitive or motor impairment (e.g., cerebral palsy, severe traumatic brain injury; milder comorbidities including learning disabilities and Attention-Deficit/Hyperactivity Disorder were allowed). The study was approved by the Institutional Review Board at all participating institutions; participants provided written informed consent in accordance with local IRB requirements.

### Study Evaluations

#### Neurocognitive Functioning

The assessment battery included neurocognitive measures with previously demonstrated sensitivity to HAND in adults<sup>15</sup>. Domains included Memory (Hopkins Verbal Learning Test-Revised<sup>16,17</sup>, HVL-T-R; Brief Visuospatial Memory Test-Revised<sup>17,18</sup>, BVMT-R), Motor Skills (Grooved Pegboard<sup>19</sup>, Timed Gait<sup>20</sup>), Attention (Wechsler Adult Intelligence Scale-III<sup>21</sup>, WAIS-III, Digit Span, Letter/Number Sequencing), and Executive Functions (Verbal Fluency<sup>19</sup>, Stroop Interference<sup>17,22</sup>, Trail Making Test<sup>23,24</sup>). Measures of general cognitive functioning (WAIS-III<sup>21</sup>), reading ability (Wide Range Achievement Test-4<sup>25</sup>), and everyday functioning (Activities of Daily Living<sup>26</sup>, ADL; Behavior Rating Inventory of Executive Function-Adult<sup>27</sup>, BRIEF-A) were included to describe the cohort and/or serve as covariates. Standard scores using published normative standards, with adjustments for age and, where available, race, Hispanic ethnicity, education and/or gender<sup>17</sup>, were computed. Scores within domains were converted to z-scores and averaged for analytic clarity and to reduce the number of regression analyses performed. In addition, neurocognitive performance was summarized using an approach developed in the adult HAND literature<sup>15,28</sup> that weights the presence and severity of neurocognitive impairment<sup>29</sup>. Deficit scores, computed using T-score conversions and ranging from 0 (T-scores>39) to 5 (T-scores<20; higher deficit scores reflect greater impairment), were averaged to derive a

global deficit score (GDS). A GDS cut-point of  $>.5$  was used to classify individuals with global neurocognitive impairment<sup>29</sup>. Individuals with  $GDS >.5$  in two or more domains were classified with HAND (syndromic HAND if they reported a decline in 2 or more ADL areas relative to best ever functioning, and otherwise Asymptomatic Neurocognitive Impairment (ANI), i.e., neurocognitive impairment on testing but no reported impact on daily functioning.)

### Psychiatric Functioning and Substance Use

Participants completed questionnaires regarding depression (Beck Depression Inventory-II; BDI-II<sup>30</sup>), general distress (Behavioral Symptom Inventory; BSI<sup>31</sup>), and frequency of using 10 different substances over three months prior to the study visit and presence of substance-related issues (e.g., missing work) used to calculate a risk index (Alcohol, Smoking and Substance Involvement Screening Test; ASSIST<sup>32</sup>). Participants were asked whether they use potentially psychoactive substances (street drugs or medications; PPS), and whether they used them on the day of testing.

### Demographics and Psychosocial History

Participants were asked about birth sex, race, ethnicity, primary language, sexual orientation, employment, school enrollment status, past 30-day income, educational attainment, educational risk (history of special education or repeating a grade), and living situation.

### Medical record abstraction

Comorbid current and past conditions were rated according to potential impact on current cognition as none, mild (e.g., headache, adjustment disorder), moderate (e.g., chronic migraines, major depressive disorder), or severe (e.g., seizure disorder, skull fracture), following published guidelines<sup>15</sup>. CD4 T-cell counts and plasma HIV-1 RNA viral load (VL) values within four weeks preceding the visit, CDC classification<sup>33</sup> and date of first positive HIV test were abstracted.

### Statistical Methods

Chi-square tests were used to compare percentages of impaired study participants with expected population percentages ( $1\sigma$  or  $2\sigma$  below the mean). Regression models were fit to memory, motor, attention, and executive function domain scores, general cognitive functioning (WAIS-III) score, mean z-score and HAND diagnosis along with a set of demographic and clinical characteristic covariates. Models were developed using a stepwise approach. Each predictor was first tested for association with each outcome in a single regression model. Covariates with critical alpha values at  $p = 0.10$  were included in a stepwise selection procedure; covariates at  $p = 0.05$  in the stepwise models were included in the final models. Measures related to HIV disease (CD4 count,  $\log_{10}$  VL, and years since first positive HIV test) were included in all multivariable models. Other covariates included age, BDI-II score, BSI score, gender, race/ethnicity, education level, language spoken at home, past 30-day income, educational risk, confounding comorbidity, PPS, and substance use risk for tobacco, alcohol, cannabis, and "other drug". Linear regression was used for all outcome measures except HAND, which was modeled using logistic regression. Final regression models were evaluated for influential outliers, collinearity, and normality and homoscedasticity of residuals. Validity of the logistic regression models was assessed using Hosmer-Lemeshow tests. Analyses were completed using SAS Version 9.2.

## Results

### Population Characteristics

220 study participants enrolled between April 2008 and July 2010 (numbers vary by outcome due to missing or invalid data). Participants had mean age 20.9 years and were predominantly male (80.4%), African-American (67.6%) or Hispanic (21.5%), self-identified as homosexual or bisexual (72.6%), and high school educated or beyond (73%), with 41.1% currently in school (Table 1). Approximately 22.4% reported repeating a grade and 22.4% had received special education; group membership overlapped but was not identical. Less than half (41.6%) were employed and 48.4% reported living with a family member.

### Clinical HIV Characteristics

Approximately half the sample had been diagnosed with HIV for less than a year (Table 2). Youth with CD4+ counts >350 accounted for 57% of the sample, with only 6% <200. Almost 90% were in CDC category A; all but 1.4% had VL >400 copies due to selection criteria for the associated treatment strategy study.

### Psychiatric Characteristics

Most (73.4%) had BDI-II scores in the minimal or mild range (Table 3); 53% exceeded the BSI clinical cut-off (T-score >63). Reported daily use frequencies were 20.4% for cannabis, 33.6% for tobacco, and 2.8% for alcohol; 23.9% reported weekly alcohol use. Other substances were less common (<10%). Comorbid conditions considered likely to have moderate or serious effects on neurocognition were diagnosed in 39% of participants. Currently using potentially psychoactive medications or substances was reported by 5.5% of participants; 2.8% reported taking them on the day of testing.

### Neurocognitive and Everyday Functioning

Impaired neurocognitive functioning was defined as either >one or >two standard deviations (SD) from published means in the direction indicating poorer performance. The percent identified as impaired using a two-SD definition exceeded the number expected in a normative sample (2.3%) for most tests, with memory and most motor domain measures indicating impairment rates >15% (Table 4). While mean GDS was 0.9, 69.4% had scores in the impaired range. More than 13% of BRIEF-A index scores also were elevated. However, only 3.67% of study participants indicated ADL declines. Regarding HAND, 62.9% of subjects had ANI and 2.4% showed syndromic HAND.

### Association of HIV Disease Indicators with Neurocognitive Summary Measures

Table 5 shows results for final adjusted regression models for association with HIV disease measures (CD4 count, log<sub>10</sub> VL, time since HIV diagnosis). Lower CD4 counts were associated with poorer performance in executive functions and higher likelihood of HAND, whereas longer time since HIV diagnosis was significantly associated with lower WAIS-III I.Q. ( $p<.05$ ). VL was not significantly associated with any neurocognitive outcomes ( $p>.10$ ).

### Association of Covariates with Neurocognitive Measures

The following measures had significant associations with neurocognitive outcomes and were used as covariates in the regression models. Meeting criteria for HAND was associated with lower education level ( $p<0.01$ ) and higher risk level for alcohol involvement ( $p<0.05$ ). Lower global functioning scores were associated with lower education level ( $p<0.01$ ), Black race ( $p<0.05$ ), educational risk ( $p<0.05$ ), diagnoses with potential moderate or severe effects ( $p<0.05$ ) and PPS ( $p<0.01$ ). Lower attention domain scores were associated with educational



risk ( $p<0.01$ ), lower education level ( $p<0.05$ ) and PPS ( $p<0.05$ ). Lower motor domain scores were associated with female gender ( $p<0.05$ ), lower education level ( $p<0.05$ ), PPS ( $p<0.05$ ) and diagnoses with potential moderate or severe effects ( $p<0.01$ ). Lower executive domain scores were associated with BSI scores indicating greater distress ( $p<0.01$ ). Lower memory domain scores were associated with lower education level ( $p<0.001$ ) and income ( $p<0.05$ ), higher risk level for alcohol involvement ( $p<0.05$ ) and PPS ( $p<0.05$ ). Lower mean z-score was associated with Black race ( $p<0.001$ ), lower education level ( $p<0.001$ ), educational risk ( $p<0.05$ ) and PPS ( $p<0.01$ ). Age, BDI-II, language spoken at home, and cannabis, tobacco or other drug involvement were not significant covariates for any neurocognitive measures.

## Discussion

In the current climate of “test and treat” emphasizing early treatment initiation<sup>34</sup>, this study represents a unique opportunity to describe neurocognitive functioning in a cohort of youth with behaviorally acquired HIV and a range of disease severity prior to initiation of cART. Study participants differed from those included in previous adult studies in their status as still developing individuals, and from perinatally infected youth in the timing and recentness of their HIV infection. Cohort demographics, predominantly minority and male, are representative of a group at high risk for acquiring HIV. The comprehensive assessment of psychiatric, substance use, and psychoeducational characteristics enabled us to examine the contribution of both HIV disease parameters and other risk factors to neurocognitive functioning.

Our findings show a strikingly high rate of impairment in some cognitive domains in youth with behaviorally acquired HIV. The number and degree of impairments resulted in the majority (~65%) of participants classified with HAND; however, few participants reported declines in daily functioning consistent with syndromic deficits, instead meeting criteria for ANI. As in the adult HIV literature, youth show high rates of impairment on tests of learning and memory, particularly verbal, with the pattern of scores suggesting difficulty with acquisition of information rather than rapid forgetting<sup>35</sup>. Similar to adults, our youth had greater than expected rates of impairment on most tests of executive functions<sup>28</sup>. In contrast to recent adult findings showing a decrease in motor impairments in the era of cART<sup>7</sup>, 16-26% of youth had significant difficulty with tests of fine or gross motor functioning. Although impairments in learning and memory, executive functions, and motor functioning are consistent with some studies of children and adolescents with pHIV<sup>6</sup>, youth with behaviorally acquired HIV showed less impairment on tests of global intellectual functioning as well as attention and working memory. Thus, youth who acquire HIV during adolescence show a unique profile of neurocognitive functioning.

The psychiatric, demographic and diagnostic profile of the study participants, discussed below, describes a cohort that faces substantial obstacles to optimal neurocognitive outcomes and daily functioning in addition to HIV infection. Nonetheless, multivariate analyses accounting for the influence of other risks show an association of cognitive functioning with measures of HIV disease severity. In contrast to the adult literature, impairment in memory and motor functions was not associated with disease severity in our cohort after accounting for other risk factors. However, HAND diagnosis, which represents impairment across domains, and lower executive function performance were significantly associated with lower current CD4 count, and lower global functioning was significantly associated with time since HIV diagnosis. Studies on adult and perinatal HIV infection have shown the greatest risk for neurocognitive impairment in the context of previous AIDS-defining diagnoses or CD4 nadirs below 200<sup>10,36</sup>. The association of current CD4 count with HAND in our cohort of youth with very low prevalence of past severe HIV disease (CDC class C <1%) is concerning since recent literature suggests subtle central nervous

system impacts early in HIV infection<sup>37</sup>. However, lack of a control group without HIV infection limits conclusions regarding relationship of neurocognitive impairments to HIV. Further research is warranted to address the possibility that adolescents with behaviorally acquired HIV may be at heightened risk for impairments resulting from early subclinical neuroimmune events while otherwise relatively healthy. Neuroimaging and investigation of inflammatory and other biomarkers may clarify the underlying mechanisms of neurocognitive impairments in YLWH.

Multivariate modeling identified psychiatric, demographic and historical characteristics of the study cohort that contribute significantly to neurocognitive outcomes and should be considered in future neurocognitive research involving YLWH. Demographic data indicate the majority of participants are in racial or ethnic minority groups and have low income, suggesting the possibility of reduced educational and enrichment opportunities and poorer nutrition, which might reduce cognitive reserve and increase risk of HAND in adulthood<sup>11</sup>. The significant association with race may reflect these factors and also may have been influenced by the unavailability of norms adjusted for ethnicity for a subset of study measures. More than one-fifth of participants reported repeating a grade or receiving special education services, and more than one-third had comorbid conditions rated as having moderate or serious potential risk for neurocognitive outcomes. The cohort profile of average intellectual abilities and significant impairment in learning and memory, along with school difficulty, suggests pre-existing learning disabilities may account at least in part for observed impairments; in fact, educational risk was significantly associated with the attention domain and summary z-score in addition to global functioning. Replication of our finding and further research regarding learning risks in this population are warranted.

Psychiatric and substance use measures indicated significant emotional and behavioral issues for many study participants. More than one-fourth of participants endorsed current moderate to severe depression, and >50% exceeded the criterion indicating potential clinically significant mental health issues (BSI). One-fifth of participants reported using cannabis daily, and one-fourth reported daily or weekly alcohol use. Each of these characteristics was significantly associated with at least one neurocognitive domain outcome in multivariate modeling with the exception of depression and cannabis use, which nevertheless suggest treatment needs for YLWH represented in our cohort. The contribution of alcohol use to HAND diagnosis is particularly concerning given previous findings showing interactive neurocognitive effects of comorbid alcoholism and HIV infection<sup>8</sup> and brain changes following initiation of heavy drinking during adolescence<sup>38</sup>.

The impairments seen in this study have potential implications for treatment of youth with behaviorally acquired HIV regardless of their origin. Relationships with study covariates suggest some of the observed impairments may be due at least in part to modifiable factors such as alcohol use/abuse, psychiatric distress, and educational disadvantage. These factors also represent treatment targets in their own right due to their influence on mental health and quality of life. The memory and learning impairments require replication and further study regarding their origin, impact on medication management and other functional outcomes and appropriate interventions. Youth with HIV are in the unique position of being in a life stage characterized primarily by acquisition and practicing of new skills critical for successful transition to adulthood. In adults with HIV, cognitive impairment has been found to affect a wide range of critical skills that are newly being acquired by youth, from driving to medication adherence; further, a reciprocal interaction has been described between cognitive impairment and adherence<sup>39</sup>. Equally worrisome is the potential impact of impairments on sexual risk behaviors<sup>40</sup> through decreased ability to exert self-control, evaluate consequences, or learn alternate coping skills. Further study of the relationship of cognitive

functioning to functional outcomes and risk behaviors in youth with behaviorally acquired HIV is needed.

The combination of premorbid cognitive impairments, socioeconomic and educational risks in this cohort raises the possibility of low cognitive reserve, which has been associated with risk for HAND and functional decline in adults with HIV<sup>41</sup>. It is unknown how pre-existing impairment might interact with HIV and ART over time following infection and treatment initiation during adolescence; e.g., cognitive impairments might interact with accelerated aging hypothesized to characterize HIV<sup>42</sup> to produce greater risk of cognitive and functional decline, or impaired youth might be predisposed to ART-related cognitive or psychiatric toxicities. For these reasons, long-term monitoring of neurocognitive functioning in youth with HIV and inclusion of neurocognitive measures in treatment studies may be warranted.

This study has several limitations. As this was a study of ART treatment strategies, a cohort without HIV was not included. Although cohort demographics match the population most at risk for new HIV infection (predominantly minority, male, and gay-identified), most study participants were youth who committed to being on study for three years and thus might not be representative of all YLWH. Youth with a range of disease severity enrolled; however, the distribution of CD4 counts was determined by desired group sizes and may differ from an unselected population. Although we used an analytic plan designed to reduce the number of comparisons performed, the number of analyses still may result in inflated Type I error. Individual neurocognitive functions may have associations with HIV disease severity or covariates not reflected by the domain summary approach taken in this manuscript. The global functioning measure has since been updated and results may differ from those that would be obtained using the new version. Measures of substance use and ADL were obtained by self-report and may underestimate these issues; in addition, the ADL measure was not developed for an adolescent population and may be less sensitive to decline in youth.

In summary, this cohort of youth age 18-24 with behaviorally acquired HIV shows a strikingly high rate of impairment in some neurocognitive domains with the potential to impact adherence as well as other functional outcomes. Further, they show high rates of psychiatric symptoms, substance use, and histories of educational and other risks. Among markers of HIV disease severity considered here, modest associations of CD4 count and time since HIV diagnosis with neurocognitive outcomes were seen. The significant neurocognitive impairment observed in our cohort highlights the need for evaluation of cognitive functioning in YLWH, studies of mechanisms underlying observed impairments, and development of interventions to lessen the impact on functional outcomes.

## Acknowledgments

We extend our sincere gratitude to Pim Brouwers, Ph.D., for his comments on earlier versions of the manuscript, and Tiandong Li, Ph.D., for statistical analysis and consultation. Portions of the findings reported herein were presented at the bi-annual meeting of the Adolescent Trials Network for HIV/AIDS Interventions, Bethesda, Maryland, in April, 2011. This work was supported by The Adolescent Trials Network for HIV/AIDS Interventions (ATN; U01-HD040533) from the National Institutes of Health through the National Institute of Child Health and Human Development (B. Kapogiannis, C. Worrell), with supplemental funding from the National Institutes of Drug Abuse (N. Borek, D. Lawrence) and Mental Health (P. Brouwers, S. Allison), and R01 DA DA031017 from the National Institutes of Drug Abuse. The study was scientifically reviewed by the ATN's Behavioral Leadership Group. Network, scientific, and logistical support was provided by the ATN Coordinating Center (C. Wilson, C. Partlow) at the University of Alabama at Birmingham. Network operations and data management support was provided by the ATN Data and Operations Center at Westat, Inc. (J. Korelitz, B. Driver). Please note that listing in the acknowledgments section does not imply endorsement of the findings and conclusions of this manuscript. We acknowledge the contribution of the investigators and staff at the following ATN 071 sites that participated in this study (listed in order of Site Principal Investigator, Study Coordinator, Psychologist). University of South Florida (Patricia Emmanuel, M.D., Priscilla Julian, RN, Tiffany Chenneville, Ph.D.); Children's Hospital of Los Angeles



(Marvin Belzer, M.D., Michelle Bradford, B.A., Anita Hamilton, Ph.D., ABPP-CN); Children's National Medical Center (Lawrence D'Angelo, M.D., Connie Trexler, RN, Donna Marschall, Ph.D.); University of Pennsylvania and the Children's Hospital of Philadelphia (Mary Tanney, M.P.H., M.S.N., C.P.N.P., Linda Hawkins, M.S., Ed.D.; Jerilynn Radcliffe, Ph.D.); Stroger Hospital and the CORE Center (Jaime Martinez, M.D., Kelly Bojan, D.N.P., Harold Fuentes, Psy.D.); University Pediatric Hospital (Irma Febo, M.D., Hazel Ayala-Flores, B.S.N., Nydia Scalley-Trifilio, M.A.); Montefiore Medical Center (Donna Futterman, M.D., Elizabeth Bruce, M.D., Erica Weiss, M.A.); Mount Sinai Medical Center, Adolescent Health Center (John Steever, M.D., Mary Geiger, M.P.H., Marijane Lehr, Ph.D.); University of California, San Francisco (Barbara Moscicki, M.D., Lisa Irish, B.S.N., Rita Jeremy, Ph.D.); Tulane Medical Center (Sue Ellen Abdalian, M.D., Leslie Kozina, RN, Patricia Sirois, Ph.D.); University of Maryland (Vicki Tepper, Ph.D., Reshma Gorle, M.P.H., Terry Lee-Wilk, Ph.D.); University of Miami School of Medicine (Lawrence Friedman, M.D., Donna Maturo, M.S.N., Anai Cuadra, Ph.D.); Children's Diagnostic & Treatment Center (Ana Puga, M.D., Amy Inman, B.S., Doyle Patton, Ph.D.); St Jude Children's Research Hospital (Patricia Flynn, M.D., Mary Dillard, B.S.N, Patricia Garvie, Ph.D., Megan Wilkins, Ph.D.); Lurie Children's Hospital (Robert Garofalo, M.D., M.P.H., Ann Sanders, M.P.H., Andrea Boyd, Ph.D.); University of Southern California (Andrea Kovacs, M.D., Michelle Aranda, M.P.H., Maribel Mejia, Ph.D.); Children's Hospital of Michigan (Ellen Moore, M.D., Ayanna Walters, RN, Salome Cockern, Ph.D.); Children's Hospital of Denver (Elizabeth McFarland, M.D., Kerry Hahn, B.S., CCRP, Robin McEvoy, Ph.D.); Howard University (Sohail Rana, M.D., Meseret Deressa, M.P.H, Eshauna Padilla, M.A.); Johns Hopkins University (Allison George Agwu, M.D., Todd Noletto, M.P.H., Laura Margolis, Ph.D.). We sincerely thank additional ATN 071 Protocol Team Members (Pim Brouwers, Ph.D., Tiandong Li, Ph.D., Craig Wilson, M.D.), the ATN Community Advisory Board, and the youth who participated in the study. An oral presentation of portions of this study was made at the bi-annual Adolescent Medicine Trials Network for HIV/AIDS Intervention Meeting in Bethesda, MD, on April 11, 2011.

## List of Abbreviations

<b>ADL</b>	Activities of daily living
<b>ANI</b>	Asymptomatic neurocognitive impairment
<b>ART</b>	Antiretroviral therapy
<b>ASSIST</b>	Alcohol, Smoking and Substance Involvement Screening Test
<b>BDI-II</b>	Beck Depression Inventory-II
<b>BRIEF-A</b>	Behavior Rating Inventory of Executive Function-Adult
<b>BSI</b>	Behavioral Symptom Inventory
<b>BVMT-R</b>	Brief Visuospatial Memory Test-Revised
<b>cART</b>	Combination ART
<b>CDC</b>	Centers for Disease Control
<b>GDS</b>	Global deficit score
<b>HAND</b>	HIV-associated neurocognitive disorders
<b>HIV</b>	Human immunodeficiency virus
<b>HVLT-R</b>	Hopkins Verbal Learning Test-Revised
<b>IRB</b>	Institutional review board
<b>pHIV</b>	Perinatally acquired HIV
<b>PMTCT</b>	Prevention of mother to child transmission
<b>PPS</b>	Potentially psychoactive substances
<b>SD</b>	Standard deviation
<b>VL</b>	Viral load
<b>WAIS-III</b>	Wechsler Adult Intelligence Scale-III
<b>WRAT-4</b>	Wide Range Achievement Test-4

**YLWH** Youth living with HIV

## References

1. Centers for Disease Control. HIV among youth. CDC HIV/AIDS Facts. Dec.2011
2. Tanney MR, Naar-King S, Murphy DA, Parsons JT, Janisse H. Multiple risk behaviors among youth living with human immunodeficiency virus in five U.S. cities. *J Adolesc Health*. Jan; 2010 46(1): 11–16. [PubMed: 20123252]
3. Eaton DK, Kann L, Kinchen S, et al. Youth risk behavior surveillance - United States, 2011. *MMWR Surveill Summ*. Jun 8; 2012 61(4):1–162. [PubMed: 22673000]
4. Woods SP, Moore DJ, Weber E, Grant I. Cognitive neuropsychology of HIV-associated neurocognitive disorders. *Neuropsychology Review*. 2009; 19(2):152–168. [PubMed: 19462243]
5. Loveland KA, Stehens JA, Mahoney EM, et al. Declining immune function in children and adolescents with hemophilia and HIV infection: effects on neuropsychological performance. Hemophilia Growth and Development Study. *J Pediatr Psychol*. Jul-Aug;2000 25(5):309–322. [PubMed: 10880061]
6. Allison, S.; Wolters, P.; Brouwers, P. Youth with HIV/AIDS: Neurobehavioral consequences. In: Paul, RH.; Sacktor, N.; Valcour, V.; Tashima, KT., editors. *HIV and the Brain: New Challenges in the Modern Era*. Humana Press; New York: 2009. p. 187-211.
7. Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. *J Neurovirol*. Feb; 2011 17(1):3–16. [PubMed: 21174240]
8. Fama R, Rosenbloom MJ, Nichols BN, Pfefferbaum A, Sullivan EV. Working and episodic memory in HIV infection, alcoholism, and their comorbidity: baseline and 1-year follow-up examinations. *Alcohol Clin Exp Res*. Oct; 2009 33(10):1815–1824. [PubMed: 19656122]
9. Rippeth JD, Heaton RK, Carey CL, et al. Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. *J Int Neuropsychol Soc*. Jan; 2004 10(1): 1–14. [PubMed: 14751002]
10. Ellis R, Badiee J, Vaida F, et al. Nadir CD4 is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. *AIDS*. 2011; 25(14):1747–1751. [PubMed: 21750419]
11. Morgan EE, Woods SP, Smith C, Weber E, Scott JC, Grant I. Lower cognitive reserve among individuals with syndromic HIV-Associated Neurocognitive Disorders (HAND). *AIDS Behav*. Jun 8.2012
12. Hinkin CH, Castellon SA, Durvasula RS, et al. Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. *Neurology*. Dec 24; 2002 59(12):1944–1950. [PubMed: 12499488]
13. Hosek SG, Zimet GD. Behavioral considerations for engaging youth in HIV clinical research. *J Acquir Immune Defic Syndr*. Jul 1; 2010 54(Suppl 1):S25–30. [PubMed: 20571420]
14. Blakemore SJ, Choudhury S. Development of the adolescent brain: implications for executive function and social cognition. *J Child Psychol Psychiatry*. Mar-Apr;2006 47(3-4):296–312. [PubMed: 16492261]
15. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. *Neurology*. Oct 30; 2007 69(18):1789–1799. [PubMed: 17914061]
16. Brandt, J.; Benedict, R. *Hopkins Verbal Learning Test-Revised*. Psychological Assessment Resources; Odessa, Florida: 2001.
17. Norman MA, Moore DJ, Taylor M, Franklin D, Cysique L, Ake C, Lazarretto D, Vaida F, Heaton RK. Demographically corrected norms for African Americans and Caucasians on the Hopkins Verbal Learning Test-Revised, Brief Visuospatial Memory Test-Revised, Stroop Color and Word Test, and Wisconsin Card Sorting Test 64-Card Version. *J Clin Exp Neuropsychol*. 2011; 33(7): 793–804. [PubMed: 21547817]
18. Benedict, R. *Brief Visuospatial Memory Test-Revised*. Psychological Assessment Resources; Odessa, Florida: 1997.

19. Strauss, E.; Sherman, EMS.; Spreen, O. A compendium of neuropsychological tests: Administration, norms, and commentary. Oxford University Press; New York, NY: 2006.
20. Robertson KR, Parsons TD, Sidtis JJ, et al. Timed Gait test: normative data for the assessment of the AIDS dementia complex. *J Clin Exp Neuropsychol*. Oct; 2006 28(7):1053–1064. [PubMed: 16840235]
21. The Psychological Corporation. WAIS-III/WMS-III technical manual. Author; San Antonio, Texas: 1997.
22. Golden, CJ.; Freshwater, SM. The Stroop Color and Word Test: A manual for clinical and experimental uses. Stoelting Co; Wood Dale, Illinois: 2002.
23. Reitan, RM.; Wolfson, D. The Halstead-Reitan neuropsychological test battery: Theory and clinical interpretation. 2nd ed. Neuropsychology Press; Tucson, AZ: 1993.
24. Mitrushina, M.; Boone, K.; Razani, J.; D'Elia, L. Handbook of normative data for neuropsychological assessment. Oxford University Press; New York, NY: 2005.
25. Wilkinson, GS.; Robertson, GJ. Wide Range Achievement Test administration manual. 4th ed. Wide Range, Inc; Wilmington, Delaware: 2006.
26. Heaton R, Marcotte T, Mindt M, et al. The impact of HIV-associated neuropsychological impairment on everyday functioning. *Journal of the International Neuropsychological Society*. 2004; 10(3):317–331. [PubMed: 15147590]
27. Roth, AT.; Isquith, PK.; Gioia, GA. Behavior Rating Inventory of Executive Function - Adult Version: Professional Manual. Psychological Assessment Resources, Inc; Lutz, Florida: 2007.
28. Heaton RK, Clifford DB, Franklin DR Jr. et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. *Neurology*. Dec 7; 2010 75(23):2087–2096. [PubMed: 21135382]
29. Carey CL, Woods SP, Gonzalez R, et al. Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. *J Clin Exp Neuropsychol*. May; 2004 26(3): 307–319. [PubMed: 15512922]
30. Beck, AT.; Steer, RA.; Brown, GK. Beck Depression Inventory Manual. 2nd ed. The Psychological Corporation, Harcourt Brace & Company; San Antonio, Texas: 1987.
31. Derogatis, LR. Brief Symptom Inventory (BSI): Administration, Scoring, and Procedures Manual. Third Edition. National Computer Systems, Inc; Minneapolis, MN: 1993.
32. World Health Organization ASSIST Working Group. The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): Development, reliability and feasibility. *Addiction*. 2002; 97:1183–1194. [PubMed: 12199834]
33. Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. *MMWR Recomm Rep*. Dec 18; 1992 41(RR-17):1–19.
34. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. *JAMA*. Jul 25; 2012 308(4): 387–402. [PubMed: 22820792]
35. Gongvatana A, Woods SP, Taylor MJ, Vigil O, Grant I. Semantic clustering inefficiency in HIV-associated dementia. *J Neuropsychiatry Clin Neurosci*. 2007; 19(1):36–42. Winter. [PubMed: 17308225]
36. Smith R, Chernoff M, Williams PL, et al. Impact of HIV severity on cognitive and adaptive functioning during childhood and adolescence. *Pediatr Infect Dis J*. Jun; 2012 31(6):592–598. [PubMed: 22592486]
37. Moore DJ, Letendre SL, Morris S, et al. Neurocognitive functioning in acute or early HIV infection. *J Neurovirol*. Feb; 2011 17(1):50–57. [PubMed: 21165782]
38. Squeglia LM, Pulido C, Wetherill RR, Jacobus J, Brown GG, Tapert SF. Brain response to working memory over three years of adolescence: influence of initiating heavy drinking. *J Stud Alcohol Drugs*. Sep; 2012 73(5):749–760. [PubMed: 22846239]
39. Ettenhofer ML, Foley J, Castellon SA, Hinkin CH. Reciprocal prediction of medication adherence and neurocognition in HIV/AIDS. *Neurology*. Apr 13; 2010 74(15):1217–1222. [PubMed: 20220123]

40. Anand P, Springer SA, Copenhaver MM, Altice FL. Neurocognitive impairment and HIV risk factors: a reciprocal relationship. *AIDS Behav.* Dec; 2010 14(6):1213–1226. [PubMed: 20232242]
41. Basso MR, Bornstein RA. Estimated premorbid intelligence mediates neurobehavioral change in individuals infected with HIV across 12 months. *J Clin Exp Neuropsychol.* Apr; 2000 22(2):208–218. [PubMed: 10779835]
42. Woods SP, Dawson MS, Weber E, Grant I. The semantic relatedness of cue-intention pairings influences event-based prospective memory failures in older adults with HIV infection. *J Clin Exp Neuropsychol.* Apr; 2010 32(4):398–407. [PubMed: 19763997]

**Table 1**

Demographic characteristics of sample (N = 219)

	Mean (SD) or Count (%)
<b>Age (years)</b>	20.9 (1.8)
Age range:	18-24
<b>Sex (% men)</b>	176 (80.4%)
<b>Transgender</b>	9 (4.1%)
<b>Ethnicity</b>	
<i>African American</i>	148 (67.6%)
<i>Hispanic</i>	47 (21.5%)
<i>Non-Hispanic white</i>	14 (6.4%)
<i>Other ethnicity</i>	10 (4.5%)
<b>Language at Home</b>	
<i>English</i>	208 (95.0%)
<i>Spanish</i>	9 (4.1%)
<i>Other</i>	2 (0.9%)
<b>Sexual Preference</b>	
<i>Straight (heterosexual)</i>	53 (24.2%)
<i>Gay/Lesbian (homosexual)</i>	136 (62.1%)
<i>Bisexual</i>	23 (10.5%)
<i>Not sure/refused to answer</i>	7 (3.2%)
<b>Educational Status</b>	
<i>Currently attending school/GED program</i>	90 (41.1%)
<b>Level of Education*</b>	
<i>Less than high school graduate</i>	59 (26.9%)
<i>High school graduate</i>	66 (30.1%)
<i>Some education after high school</i>	80 (36.5%)
<i>College graduate or above</i>	14 (6.4%)
<b>Repeated a Grade</b>	49 (22.4%)
<b>Special Class/Special Education</b>	49 (22.4%)
<b>Currently Employed</b>	
<i>Full-time</i>	51 (23.3%)
<i>Part-time</i>	40 (18.3%)
<i>Not employed</i>	127 (58.0%)
<i>Omitted</i>	1 (0.5%)
<b>Living Situation</b>	



	Mean (SD) or Count (%)
<i>Independent</i>	75 (34.2%)
<i>With Family member</i>	106 (48.4%)
<i>With Non-family member</i>	28 (12.8%)
<i>Other</i>	10 (4.6%)
<b>Estimated Monthly Income (in dollars)</b>	
<50	86 (39.3%)
51-499	63 (28.8%)
500-999	27 (12.3%)
1,000-2,999	37 (16.9%)
>3,000	1 (0.5%)
<i>Unknown or refused to answer</i>	5 (2.3%)

\* "High school graduate" includes those participants who earned a GED.

**Table 2**

Clinical HIV characteristics (N = 219)

	Count (%)
<b>Time since HIV diagnosis (months)</b>	
< 4	49 (22.4%)
4 – 11	63 (28.8%)
12 – 26	51 (23.3%)
≥ 27	56 (25.6%)
<b>Current CD4 count (cells/mm<sup>3</sup>)</b>	
Mean (standard deviation)	441.6 (216.3)
Median (IQR)	397.5 (247.0)
Range	16-1,167
<b>Current CD4 Count (cells/mm<sup>3</sup>)</b>	
CD4 < 200	13 (5.9%)
CD4 = 200-349	82 (37.4%)
CD4 = 350-499	55 (25.1%)
CD4 ≥ 500	69 (31.5%)
<b>Current CD4 Percent</b>	
< 15%	28 (12.8%)
15% - 24%	92 (42.0%)
>24%	99 (45.2%)
<b>CDC Clinical Classification</b>	
Category A	192 (87.7%)
Category B	25 (11.4%)
Category C	2 (0.9%)
<b>Viral Load (HIV-1 RNA copies/mL, Plasma)</b>	
< 400	3 (1.4%)
400 – 10,000	86 (39.3%)
10,001 – 100,000	110 (50.2%)
100,001 – 500,000	18 (8.2%)
> 500,000	2 (0.9%)

**Table 3**

## Psychiatric characteristics

	N	Mean (SD) or Count (%)
<b>Beck Depression Inventory, 2<sup>nd</sup> Ed. (BDI-II)</b>	218	13.9 (10.5)
<i>Mean Score</i>		
<i>Categories (%)</i>		
Minimal (< 13)		124 (56.9%)
Mild (14-19)		36 (16.5%)
Moderate (20-28)		36 (16.5%)
Severe (>28)		22 (10.1%)
<b>Brief Symptom Inventory (BSI)</b>	218	
Global Severity Index		63.5 (11.6)
Percent exceeding clinical cutoff <sup>1</sup>		116 (53.2%)
<b>Frequency of Alcohol Use (past 3 mo.)</b>	218	
None		46 (21.1%)
1 or 2 times		82 (37.6%)
Monthly		27 (12.4%)
Weekly		55 (25.2%)
Daily		8 (3.7%)
<b>Alcohol Risk (past 3 mo.)<sup>b</sup></b>	218	
None		46 (21.1%)
Low		102 (46.8%)
Moderate		62 (28.4%)
High		8 (3.7%)
<b>Frequency of Cannabis Use (past 3 mo.)<sup>b</sup></b>	218	
None		109 (50.0%)
1 or 2 times		38 (17.4%)
Monthly		7 (3.2%)
Weekly		21 (9.6%)
Daily		43 (19.7%)
<b>Cannabis Risk (past 3 mo.)<sup>b</sup></b>	218	
None		109 (50.0%)
Low		13 (6.0%)
Moderate		83 (38.1%)
High		13 (6.0%)
<b>Frequency of Tobacco Use<sup>b</sup></b>	218	
None		90 (41.3%)
1 or 2 times		24 (11.0%)

	N	Mean (SD) or Count (%)
Monthly		17 (7.8%)
Weekly		18 (8.3%)
Daily		69 (31.7%)
<b>Tobacco Risk (past 3 mo.)<sup>b</sup></b>		
	218	
None		90 (41.3%)
Low		6 (2.8%)
Moderate		102 (46.8%)
High		20 (9.2%)
<b>Comorbid or Contributing Condition(s)</b>		
	218	
None		114 (52.3%)
Mild		19 (8.7%)
Moderate		75 (34.4%)
Serious		10 (4.6%)
<b>Taking potentially psychoactive medications or substances</b>		
	217	12 (5.5%)
<b>Potentially Psychoactive Substances on Day of Testing</b>		
	217	6 (2.8%)

<sup>a</sup> A t-score of 63 was used as the clinical cutoff per author recommendations

<sup>b</sup> From the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). Substances assessed included tobacco, cannabis, alcohol, cocaine, amphetamines, inhalants, sedatives, hallucinogens, opiates, and other.

Table 4

## Neurocognitive and everyday functioning

	N	Mean (SD)	Count (%) Impaired <sup>1</sup>	1 below mean	2 below mean	P-value <sup>2</sup>
<b>Neurocognitive Functioning<sup>3</sup></b>						
<b>Global Functioning</b>						
WAIS-III Full Scale I.Q. Estimate	218	-0.35 (0.76)	43 (19.73%)		2 (0.92%)	0.173
<b>Reading Skill</b>						
WRAT- <sup>a,b</sup> single word reading	215	-0.74 (0.91)	74 (34.42%)		15 (6.98%)	<.0001
<b>Memory Domain</b>						
HVLT-R <sup>a,b,c</sup> Total Learning	218	-1.45 (1.10)	135 (61.93%)		71 (32.57%)	<.0001
HVLT-R Delayed Recall	217	-1.43 (1.27)	120 (55.30%)		86 (39.63%)	<.0001
BVMT-R <sup>a,b,c</sup> Total Learning	214	-1.07 (1.32)	106 (49.53%)		54 (25.23%)	<.0001
BVMT-R Delayed Recall	214	-0.78 (1.35)	96 (44.86%)		39 (18.22%)	<.0001
<b>Attention Domain</b>						
WAIS-III Digit Span	218	-0.29 (0.87)	36 (16.52%)		1 (0.46%)	0.070
WAIS-III Letter/Number Sequencing	217	-0.36 (0.83)	31 (14.28%)		4 (1.84%)	0.654
<b>Executive Domain</b>						
Verbal Fluency <sup>b</sup> - FAS	214	-0.47 (1.01)	60 (28.04%)		15 (7.01%)	<.0001
Verbal Fluency - Animals	214	-0.25 (1.02)	49 (22.90%)		8 (3.74%)	0.160
Stroop <sup>a,b,c</sup> Interference	214	0.09 (0.86)	17 (7.94%)		0 (0.00%)	0.061
Trail Making Test <sup>b</sup> (TMT) Part B	216	-0.51 (1.49)	64 (29.63%)		33 (15.28%)	<.0001
<b>Motor Domain</b>						
WAIS-III Digit Symbol	218	-0.60 (0.80)	49 (22.48%)		2 (0.92%)	0.173
Grooved Pegboard <sup>a,b</sup> (dominant)	211	-1.01 (1.24)	95 (43.60%)		38 (18.01%)	<.0001
Grooved Pegboard (nondominant)	210	-1.34 (1.42)	110 (52.38%)		54 (25.71%)	<.0001
Timed Gait <sup>b</sup>	209	-0.24 (2.02)	70 (33.49%)		34 (16.27%)	<.0001
<b>Global Deficit Score (GDS)<sup>1</sup></b>	216	0.9 (0.7)	150 (69.44%)			<.0001
<b>Everyday Functioning<sup>1</sup></b>						



	N	Mean (SD)	Count (%) Impaired <sup>1</sup>	P-value <sup>2</sup>
<i>BRIEF<sup>d</sup></i>				
Metacognition Index	213	0.45 (1.13)	42 (19.7%)	<.0001
Behavior Regulation Index	213	0.30 (1.08)	38 (17.8%)	<.0001
Global Executive Composite	213	0.19 (1.01)	29 (13.6%)	<.0001
<i>ADL areas declined</i>	218	0.20 (0.70)	31 (3.67%)	–
<b>HIV-Associated Neurological Disease (N = 215)</b>				
Normal			75 (34.9%)	<.0001
HIV-Associated Neurocognitive Disorder (HAND):				
Asymptomatic Neurocognitive Impairment (ANI)			135 (62.8%)	
Syndromic			5 (2.3%)	

Scores were corrected according to published norms by age (all tests except ADL).

<sup>a</sup> gender,

<sup>b</sup> education,

<sup>c</sup> race/ethnicity.

<sup>1</sup> Impairment levels were defined as follows. For all neurocognitive functioning measures, impairment was defined as either one or two standard deviations below the mean as indicated by column headings. Global deficit scores of 0.5 or greater were defined as impaired. BRIEF scores of 1.5 standard deviations or greater were defined as impaired. IADL was defined as impaired if there were two or more areas of decline.

<sup>2</sup> P-values shown are for < 2σ and reflect comparison with expected percentages. All p-values for < 1σ were significant (p < 0.01) except for WAIS-III Full Scale IQ estimate (p=0.131), WAIS-III Digit Span (p=0.828), and WAIS-III Letter/Number Sequencing (p=0.480).

<sup>3</sup> All neurocognitive measures reported as z-scores.

**Table 5**  
Summary of final regression models for association of HIV disease measures with neurocognitive outcomes

Outcome variables	CD4 count <sup>1</sup>				log <sub>10</sub> viral load				Years since first positive HIV test <sup>2</sup>					
	Regression effect/odds ratio <sup>3</sup>		Upper 95% CI		Regression effect/odds ratio <sup>3</sup>		Lower 95% CI		Regression effect/odds ratio <sup>3</sup>		Lower 95% CI		Upper 95% CI	
	effect/odds ratio <sup>3</sup>	Lower 95% CI	Upper 95% CI	p-value	effect/odds ratio <sup>3</sup>	Lower 95% CI	Upper 95% CI	p-value	effect/odds ratio <sup>3</sup>	Lower 95% CI	Upper 95% CI	p-value		
Global														
Functioning	0.339	-0.076	0.755	0.109	0.801	-0.616	2.218	0.266	-0.644	-1.252	-0.037	0.038		
Attention Scale	0.002	-0.045	0.049	0.927	-0.046	-0.205	0.114	0.574	-0.038	-0.108	0.031	0.278		
Motor Scale	0.020	-0.037	0.078	0.482	-0.004	-0.204	0.196	0.966	-0.031	-0.122	0.060	0.504		
Executive Scale	0.063	0.015	0.110	0.010	0.141	-0.022	0.304	0.089	-0.059	-0.128	0.010	0.096		
Memory Scale	0.040	-0.023	0.103	0.209	0.046	-0.166	0.259	0.668	-0.029	-0.121	0.062	0.527		
Mean z-score	0.029	-0.011	0.070	0.150	0.056	-0.083	0.194	0.428	-0.036	-0.096	0.024	0.244		
HAND	0.820	0.708	0.950	0.008	0.701	0.430	1.145	0.156	0.988	0.792	1.231	0.912		

<sup>1</sup> Model for CD4 count shows change per 100 cell increase.

<sup>2</sup> Models for duration of HIV show change per one year increase in duration.

<sup>3</sup> Models adjusted for race/ethnicity, education level, gender, income, concomitant medications that might affect performance, alcohol use severity index, Brief Symptom Inventory, diagnoses potentially affecting performance, and education risk (special classes/repeated year). See Results for further details.